Ion exchange resins transforming drug delivery systems

Current Drug Delivery

Volumn 7, Issue 3, 2010, Pages 252-262

  Gupta, Shweta ^a   Benien, Parul ^a   Sahoo, P K ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Gastroretentive; Ion exchange resins; Iontophoretic system; Orodispersible tablet; Pennkinetic system; Sigmoidal release; Superdisintegrants; Taste masking

Indexed keywords

ANION EXCHANGE RESIN; AZITHROMYCIN; BETAXOLOL; CATION EXCHANGE RESIN; CHLOROQUINE; CIPROFLOXACIN; DEXTROMETHORPHAN; DISINTEGRATING AGENT; DOXORUBICIN; ION EXCHANGE RESIN; LIPOSOME; NORFLOXACIN; POLACRILIN; VERAPAMIL; VINBLASTINE; DELAYED RELEASE FORMULATION; DRUG; DRUG CARRIER; EXCIPIENT;

ARTICLE; CANCER THERAPY; DISSOLUTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FIBER; GASTROINTESTINAL TRACT; HUMAN; IONIC STRENGTH; MICROENCAPSULATION; NONHUMAN; PH; PRIORITY JOURNAL; SIGMOID; TABLET; TASTE ACUITY; ANIMAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DELAYED RELEASE FORMULATION; DEVICES; DRUG ADMINISTRATION ROUTE; MEDICINAL CHEMISTRY; SOLUBILITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; ION EXCHANGE RESINS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 77954675721     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791560955     Document Type: Article

References (142)

1. Schlichting, D.A. Ion exchange resin salts for oral therapy. J. Pharm. Sci., 1962, 51, 134-136.
2. Chaudhry, N.C.; Saunders, L. Sustained release of drugs from ion exchange resins. J. Pharm. Pharmacol., 1956, 8, 975-986.
3. Anand, V.; Kandarapu, R.; Garg, S. Ion exchange resins: carrying drug delivery forward. Drug Discov. Today., 2001, 6, 905-914.
4. nd ed.; Wiley & Sons: Toronto, 2002, pp. 39-47.
5. International Union of Pure and Applied Chemistry; Definitions of terms relating to reactions of polymers and to functional polymeric materials (IUPAC Recommendations 2003). Pure Appl. Chem., 2004, 76 (4), 889-906.
6. th ed.; 2007, 2, pp. 662.
7. Bhalekar, M.; Avari, J.G.; Jaiswal, S.B. Cation-exchanger in pharmaceutical formulation. Indian J. Pharm. Sci., 2004, 38 (4), 184-187.
8. th ed.; 2005, pp. 94-96.
9. Swarbik, J. Ion Exchange Resins and Sustained Release. Encyclopedia of Pharmaceutical Technology, 2003, pp. 203-217.
10. Harland, C.E. Ion Exchange: Theory and Practice, 1994, 1.
11. Zagorodni, A. A. Ion Exchange Materials: Properties and Applications, Elsevier, Amsterdam, 2006.
12. st ed. CRC Press: Florida, 1991, pp. 215-230.
13. Kleinert, H.D.; Baker, W.R.; Stein, H.H. Pharm. Tech, 1993, 17, 30.
14. Douglas; Stephen, J. Drug adsorbates. U. S. Patent 5,219,563. June 15, 1993.
15. rd ed. Ann Arbor science Publisher, 1972, pp. 2.
16. Borodkin, S.; Sudanberg, D.P. Chewable tablets including coated particles of pseudoephedrine weak cation exchange resin. U. S. Patent 3,594.470, 1971.
17. Plaizier-Vercammeu, J.A. Investigation of bioavailability of codeine from a cation-exchange sulfonic acid. 1. Effect of parameters. Int. J. Pharm., 1992, 85, 45-50.
18. Lu, M.F. A polymer carrier system for taste masking of macrolide antibiotics. Pharm. Res., 1991, 8, 706-712.
19. Manek, S. P.; Kamat, V. S. Evaluation of Indion CRP 244 and Indion CRP 254 as sustained release and taste masking agents. Indian J. Pharm. Sci., 1981, 26, 773-776.
20. Nanda, A.; Garg, S. An update on taste masking technologies for oral pharmaceuticals. Indian J. Pharm. Sci., 2002, 64, 10-17.
21. Lange, P. M. Preparation and use of ion-exchange resins loaded with quinolone carboxylic acid derivatives. U. S. Patent 5, 152, 986.
22. Wen, B.R.; Miachel, P, Scheurer; Hein, Rich, Dokuzovic Antitussive drugs delivered by ion-exchange resin. U. S. Patent 6,001, 392, 1997.
23. Arup, K.; Sen Gupta Ion exchange and solvent extraction: A series of advances, 2007, 10-141.
24. Bice, W. O.; Koble, R. A. Filtering process and apparatus. U. S. Patent 3, 152, 986, 1960.
25. N.C. Chaduhary. J.Pharma. Pharmacol., 1956, 38, 975-986.
26. Siegel, S. J. Pharm. Sci., 1962, 51 (2), 1069.
27. Roy, G.M. Pharm.Tech., 1994, 62.
28. Howell; Thomas, J; Paterson; William G; Pattison Ion exchange resins.
29. Bess U. S. Patent 0,204,559, 2004.
30. Avari, J. G.; Bhalekar, M. Cation exchange resins for taste masking and rapid dissolution of Sparfloxacin. Indian Drugs, 2004, 41(1), 19-23.
31. Radebaugh, J.T. U. S. Patent 4,851,226, 1989.
32. Ainley, W.; Paul, J. Handbook of Pharmaceutical excipients, Wedder Ed.; 1994.
33. Grasono, Alesandro U. S. Patent 6,197,336, 2001.
34. th ed.; 862.
35. Purnima, A.; Namita, P.; Anita, W. Indion 414 as superdisintegrant in the formulation of mouth dissolve tablets. Ind. J. Pharm. Sci., 2006, 68 (1), 117-119.
36. Lyn, Hughes Pharmagenric. 2004, 1-3.
37. Christ, A.G. Process for the conditioning of ion-exchange resin. U. S. Patent 5,443,740 August 22, 1995, 15-58.
38. Mehendale, S.V.; Malshe, V.C. Eastern Pharmacist., 1991, 41.
39. Kamet, V.S. Ind. J. Pharm. Sci., 1981, 43, 209.
40. Chaudhari, K.P.R.; Rao, Rama, N. Indian Drugs., 1988, 35 (6), 368-371.
41. Liberman, H. A.; Lachman, L.; Schawstr, J. B.; Pharmaceutical Dosage forms tablets. 1989, 2, 173-177.
42. Van, Abbe N. J.; Rees, J. T. Amberlite resin XE-88 as a tablet disintegrant. J. Am. Pharm. Assoc. Sci., 1998, 47, 477.
43. Kamat, V. S.; Manek, S. P. Evaluation of ion-exchange resin Indion-234 as a tablet disintegrant. Indian Drugs., 1980, 307-310.
44. Upadhye, A. A.; Ambike, A. A.; Mahadik, K. R.; Paradkar, A. Application of ion exchange resins in floating drug delivery systems. Drug Dev. Ind. Pharm., 2008, 34 (10), 1117-1124.
45. Kouchak, M.; Atyabi, F. Ion exchange: an approach to prepare an oral floating drug delivery system for Diclofenac. Iran J. Pharm. Res., 2004, 2, 93.
46. Irwin, W. J. Drug delivery by ion exchange: Release of acidic drugs from anionic exchange resinate complexes. Drug Dev. Ind. Pharm., 1990, 16, 883-890.
47. Atyabi, F.; Sharma, H. L.; Mohammad, H. A. H.; Fell, J. T. Controlled drug release from coated floating ion-exchange resin beads. J. Control Release., 1996, 42, 25.
48. Fell, T. J. Prolonged gastric retention using floating dosage forms. Pharm. Technol., 2000, 82-88.
49. Atyabi, F. In vivo evaluation of a novel gastric retentive formulation based on ion-exchange resins. J. Control Release, 1996, 42, 105-113.
50. Ko, H.; Royer, M. E. In vitro binding of drugs to Colestipol hydrochloride. J. Pharm. Sci., 1990.
51. Washington, N.; Wilson, C. G.; Greaves, J. L.; Norman, S., Peach, J. M.; Pugh, K. A gamma scintigraphic study of gastric coating by micronised ion - exchange resin delivered as expidet tablet and liquid formulation in healthy volunteers. Intl. J. Pharm., 1989, 57, 17.
52. Jackson, S. J.; Bush, D.; Perkins, A.C. Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and Sucralfate. Int. J. Pharm., 2001, 212, 55.
53. Barreto; Zuniga, R.; Maruyama, M.; Kato, Y.; Aizu, K.; Ohta, H.; Takekoshi, T.; Bernal, S. F. Significance of Helicobacter Pylori infection as a risk factor in gastric cancer: serological and histological studies. J. Gastroenterol., 1997, 32, 289.
54. Burton, S. Intragastric distribution of ion-exchange resins: a drug delivery system for the topical treatment of the gastric mucosa. J. Pharm. Pharmacol., 1995, 47, 901-908.
55. Chen, Y.; Burton, M. A.; Coddle, J. P.; Napoli, S.; artins, I. J.; Gray, B. N. Evaluation of ion-exchange microshperes as carrier for anticancer drug Doxorubicin: in vitro studies. J. Pharm. Pharmacol., 1992, 44, 211.
56. Jones, C. In vitro release of cytotoxic agents from ion exchange resins. J. Control. Release., 1989, 8, 251-257.
57. Lu, J. Y.; Lowe, D. A.; Kennedy, M. D.; Low, P. S. Folate targeted enzyme prodrug cancer therapy utilizing Penicillin V amidase and a doxorubicin prodrug. J. Drug Target., 1999, 7, 43
58. Range, V.V.; Hollinger, M. A. Drug Delivery systems., 1996, 73-76.
59. Coddle, J. P.; Lumsden, A. J.; Napoli, S. Burton, M. A.; Gray, B. N. A Comparative study of anticancer efficiency of Doxorubicin carrying microshperes and liposomes using a rat live tumor model. Anticancer Res., 1993, 13, 539.
60. Sawaya, A. Binding mechanism of Doxorubicin in ion exchange albumin microcapsules. J. Pharm. Sci., 1987, 76, 475-480.
61. Wu, X.Y.; Liu, Z. Bendayan, R. Development of a particulate system with surface-immobilized chemosensitizer. Pharm. Res., 1996, 13 (9), 9303.
62. Raghunathan, Y. Prolonged release pharmaceutical preparations. U.S. Patent 4,221,778, 1980.
63. Raghunathan, Y.; Amsel, L.; Hinsvark, O. Sustained release drug delivery systems I: Coated ion exchange resin systems for Phenyl-propanloamine and other drugs. J. Pharm. Sci., 1981, 70, 379-384.
64. nd ed.; 2004; pp. 176-177.
65. nd ed.; 1992; pp. 31-32.
66. th ed.; 2005; p. 397.
67. Kim, C.J., Controlled release dosage form design., 193.
68. Sellassie, I.G.; Multiparticulate oral drug delivery, 1994, 149-150.
69. nd Ed.; 2008, 2, p. 886.
70. Delysm data sheet, Fisons Corporation, Pennwalt Pharmaceuticals Division, Rochester, NY, 1982.
71. D.A. Graves.; M. T. Wecker.; M. C. Meyer.; A. B. Stranghn.; L. A. Amsel.; O. N. Hinsvark.; A. K. Bhargava.; K. S. Rotenberg. Biopharm. Drug. Dipos. 1988, 9, 267.
72. Hui, H. Design and fabrication of oral controlled release drugdelivery systems. Marcel Dekker., USA, 1987, pp. 412-414.
73. Bhatti, A.; Singh, T.; Shishu. Preparation of tablets rapidly disintegrating in saliva containing bitter taste-masked granules by compression method. Indian. J. Pharm. Sci., 2008, 8-84.
74. Kim, C.J. Ion-exchange resins, Drug Delivery Systems, Technonic Publishing Inc., Lancaster, PA, 2000.
75. Kurwoski, M. The efficacy and relative bioavailability of diclofenac resinate in rheumatoid arthritis patient. Int. J. Clin. Pharmacol. Ther., 1994, 32, 433-440.
76. Irwin, W. J.; Belaid, K. A. Drug delivery by ion-exchange Part-I: Ester prodrugs of Propranolol. Drug Dev. Ind. Pharm., 1987, 13, 2017-2031.
77. Burke, G.M. Investigation of the applicability of ion-exchange resins as sustained release drug delivery systems for propranolol hydrochloride. Drug Dev. Ind. Pharm., 1986, 12, 713-732.
78. Bhasker, R. Novel method to evaluate diffusion controlled release of drug from resinate. Int. J. Pharm., 1986, 28, 59-66.
79. Tagalpallewar, A.; Prabhakar, B.; Gaud, R. S. Parma's best kept secret: www.expressonline.com (accessed 16-30 June, 2007).
80. Cuna, M. Controlled release liquid suspensions based on ionexchange particles entrapped within acrylic microcapsules. Intl. J. Pharm., 2000, 199, 151-158.
81. Ichikawa, H.; Fujioka, K.; Adeyeye, M. C.; Fukumoriy. Use of ionexchange resin to prepare 100mm-sized microcapsules with prolonged-drug release by the Wuster process. Int. J. Pharm. 2001, 216, 1107-1116.
82. Pongjanyakul, T.; Prakongpan, S.; Rungsardthong, U.; Chancham, P.; Priprem, A. Characteristics and in vitro release of dexteromethorphan resinates. Powder Techn., 2005, 152, 100-106.
83. Rathbone, M. J.; Adgraft, J.; Roberts, M. S. In Modified drug delivery technology, 2003
84. Sheumaker, Jerry, L. Liquid prolonged released pharmaceutical formulation containing ionic constituent; U. S. Patent 4,762,709, 1988, 9 August.
85. Nujoma, Y. N. Dissertation, Temple University, Philadelphia, 1998. [16] Bellamy, Simon, A.; Hughes, L. Method for the anhydrous loading of nicotine onto ion exchange resins. U. S. Patent 6,607,752, Aug 19, 2003.
86. Zhi-Yan, Zhang.; Qi-Neng, Ping.; Bin, Xiao. Microencapsulation and characterization of tramadol-resin complexes. Journal of Control. Release., 2000, 66, 107-113.
87. Kadam, A. U.; Sakarkar, D. M.; Kawtikwar, P. S. Development and evaluation of oral-controlled release Chlorpheniramineion exchange resinate suspension. Ind. J. Pharm. Sci., 2008, 70 (4), 531-534.
88. Liu, H. F.; Zhang, C. Y.; Li, X.; Zhao, X.; Sun, T. H.; Ju, C.Y.; Li, N.; Pan, W. S. Study of the formulation parameters affecting the preparation of microencapsulated ion-exchange resins containing venflaxacine hydrochloride. Ind. J. Pharm. Sci., 2007, 69 (4), 550-555.
89. Khan, S.; Ghua, A.; Yeole, P. G.; Katariya, P. Strong cationexchange resin for improving physicochemical properties and sustaining release of Ranitidine hydrochloride. Ind. J. Pharm. Sci., 2007, 69 (5), 626-632.
90. Lee, V. H.; Robinsonin, J. R. Sustained and controlled release drug delivery systems, Marcel Dekker: New York, 1978, p. 123.
91. Schacht, E. H. Ionic Polymers as drug carriers in controlled Drug Delivery. Bruck Ed.; CRC Press, Baton Rouge, 1984, Vol. 1, p. 49.
92. Kim C. J.; Lee, P. I. Constant rate drug release from novel anionic gel beads with transient composite structure. Control Release Bioact. Mater., 1992, 19, 162.
93. Ritschel, W. A.; Ariens, E. J. Drug dosing. Academic press, New York, 1973, Vol. 4, p. 37.
94. Hewei, L. I.; Wang, M.; Linyan, W. E. P. Patent. 1803446, 2005.
95. Schiermeier, S.; Schmidt, P. C. Fast dispersible ibuprofen tablets. Euro. J. Pharm. Sci., 2002, 15, 295-305.
96. Dobetti, L. Fast-melting tablets: development and technologies. Pharm.Technol. Drug Deliv., 2001, 44-45.
97. Calper, M.; Bodmeler, R. Modified conventional hard gelatin capsules as Fast dissolving dosage forms in the oral cavity. Eur. J. Pharm. Biopharm., 2006, 62, 178-184.
98. Sastry, S. V.; Nyshadham, J. R., Fix, J. A. Recent technological advances in oral drug delivery, A review. Pharm. Sci. Technol. Today., 2000, 3 (4), 138-145.
99. CDER, Centre for Drug Evaluation and Research (2007) Draft Guideline Guidance for Industry: Orally Disintegrating Tablets. Office of training and Communication CDER, Fishers Lane, Rockville, MD, Available from URL:http://www.fda.gov/ cder/guidance/index.htm [accessed April 2008].
100. Gupta, S. M. Pharm dissertation. Formulation and evaluation of oral disintegrating tablet of Itopride hydrochloride using ion exchange resins as drug carrier. 2009, 30 August.
101. Illum, L. Nasal drug delivery composition containing nicotine. U. S. Patent 5,935,604, July 1, 1996.
102. Mizushima, Y. Medicaments for nasal administration. U. S. Patent 5,942,242, 1996.
103. Chemdraw software.
104. Jain, N. K.; Advanced Drug Delivery System, 1st ed.; 2005; pp. 290-302.
105. Jani, R.; Harris. Sustained release comfort formulation for glaucoma therapy. U. S. Patent. 4,911,920, 1990.
106. Jungherr, L. B.; Ottoboni, T. B. Ocular microshperes delivery system. U. S. Patent 5,837,226, 1998.
107. Jani, R.; Gan, O.; Ali, Y.; Rodstrom, R.; Hancock, S. Ion exchange resins for ophthalmic delivery. J. Ocul Pharmacol., 1994, 10 (1), 57-67.
108. Moreau, J. M.; Green, L. C.; Engel, L. S.; Hill, J. M.; O Callaghan, R. J. Effectiveness of Ciprofloxacin - polystyrene sulfonate, Ciprofloxacin ofloxacin in Staphlococcus keratitis model. Curr. Eye Res., 1998, 17 (8), 808.
109. Hussain, M. A.; Di Luccio.; R. C. Shefter. E. Pharm. Res., 1989, 6, 49-52.
110. Di Luccio. Manufacture of Hollow fine tubular drug delivery systems. U. S. Patent 4,720,384, January 19, 1998.
111. Albers, J. H. M. Proc. Intl. Symp. Contr. Rel. Bioact. Mater., 1985, 12, 49-50.
112. Ahn, S. S. U. S. Patent 5,538,735, 1996, Jul 23.
113. Narisawa, S.; Nagata, M.; Danyoshi, C.; Yoshino, H.; Murata, K.; Hirakawa, Y.; Noda, K. An organic acid induced sigmoidal release system for oral controlled release system preparations. Pharm. Res., 1994, 11, 111-116.
114. Li, V. H. K. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems in controlled drug delivery. 1987, 3-94.
115. Narisawa, S. An organic acid-induced sigmoidal release for oral controlled release preparations. J. Pharm. Sci., 1996, 85, 184-188.
116. Rai, R.; Srinivas, C. R. Indian J. Dermatol., 2005, 71 (4).
117. Conaghey, M. Int. J. Pharm. 1998, 170, 225-237.
118. Jaskari, T. J. Control. Release. 2000, 67, 179-190.
119. Phipps, U. S. Patent 5,871,460, Feb 16, 1999.
120. Buchi, J. Technical applications of ion exchange. J. Pharm. Pharmacol., 1958, 8, 369-381.
121. Aberman, S. Transport of drugs across porous ion-exchange membranes. J. Control. Release., 1998, 50, 153-156.
122. Akerman, S. Adsorption of drugs onto a polyacrylic acid grafted cation-exchange membrane. Eur. J. Pharm. Sci., 1999, 9, 137-143.
123. Ito, Y. An insulin releasing system that is responsive to glucose. J. Control. Release., 1989, 10, 195-203.
124. Hismitsu, I. Glucose responsive gel from phenylborate polymer and polyvinyl alcohol: Permit response at physiological pH through the interaction of borate with ammonium group in the gel. Pharm. Res., 1997, 14 289-293.
125. Gilpin, J. A.; Patric, J.; Roger, A. Adsorption recovery of rifamycin B and rifamycin S using basic ion exchange resins. U. S. Patent 4,402,877, September 6, 1983.
126. Nauman,; Gunther,; Pieper,; Gustav,; Rehberg. Dental composition and appliances containing ion-exchange resins. U. S. Patent 3978206, August 31, 1976.
127. Richard, C. C. Microbiocidal macroreticular ion-exchange resins, their method of preparation and use. U. S. Patent 4076622, February 28, 1978.
128. Santi, K. Process for separating glucose and mannose with calcium/ ammonium exchanged ion-exchange resin. U. S. Patent 4,837,315, June 6, 30-77, 1989.
129. Tanaka, H.; Nakagawa, T.; Okabayashi, Y.; Akoyama, H.; Tanaka, T.; Itoh, K.; Chikuna, M.; Saito, Y.; Sakurai, H.; Nakayama, M. Development of ion-exchange resins and their application to analytical chemistry. Pure Appl. Chem., 1987, 59 (4), 537-578.
130. Chaubal, M. V. Synthetic polymer based ion exchange resins. Drug Deliv. Technol., 2006, 6-8.
131. Hughes, L.; Gheris, A. A new method of charactesing the buccal dissolution of drug; Rohm and Haas research Laboratory, Spring house, PA, USA.
132. Omaima, A.; Sammour, Mohammed, A.; Hammad. formulation and optimization of mouth disslove tablets containing rofecoxib solid dispersion. AAPS Pharm.Sci Technol., 2006, 7 (2).
133. Yan, Chen.; Bruce Nathaniel Gray. Controlled released preparation for cytotoxic or cytostatic drug. U. S. Patent 5,307,162, 3 August. 1999.
134. Skiri, H.; Knebelmann, B. Nephrotic syndrome associated with inflammatory bowel disease treated by Mesalzine, 1998, 79.
135. Payne, W.W.; Ion-exchange resins in clinical medicine. J. Pharm. Pharmacol., 8, 397-402.
136. Witzman, J.L. Drug used in the treatment of hyperlipoproteinemias. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 875-879.
137. Bergwitz-Larsen. U. S. Patent, 5,643,560, 1997, July.
138. Wen, U. S. Patent 6,001,392, 1999, 14 Dec.
139. Patil, A.S. U. S. Patent 0,072,545 AI, 2002, 13 June.
140. Nauman.; Gunther.; Pieper.; Gustav.; Rehberg. Dental composition and appliances containing anti-carious ion-exchange resin. U. S. Patent 3,978,206, 31 August, 1976.
141. Pandit, J.K.; Singh S.; Muthu, MS. Controlled release formulation in Neurology practice. Ann. Indian Acad. Neurol., 2006, 9, 207-216.
142. McClelland. U. S. Patent 4,976967, 1990, 11 Dec.